Bristol-Myers Squibb vs Stryker

Bristol-Myers Squibb (BMY), health care, and Stryker (SYK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bristol-Myers Squibb is worth $124.7B on the stock market and Stryker $120.1B: Bristol-Myers Squibb is valued at 4% more. Bristol-Myers Squibb trades at 13.5 times earnings and Stryker at 33.6. Over the past year Bristol-Myers Squibb's share price has moved +33.7% and Stryker's -13.6%.

Key facts

Bristol-Myers Squibb market value
$124.7B
Stryker market value
$120.1B
Bristol-Myers Squibb P/E
13.5
Stryker P/E
33.6
Bristol-Myers Squibb revenue
$48.2BFY to 2025-12-31
Stryker revenue
$25.1BFY to 2025-12-31
Superinvestors holding both
3

Market values as of .

Bristol-Myers Squibb vs Stryker: every measure side by side
Measure Bristol-Myers Squibb Stryker
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$124.7Bhigher$120.1Blower
Revenue$48.2Bhigher$25.1Blower
Earnings$7.1Bhigher$3.2Blower
Employees32,500lower56,000higher
Total assets$90Bhigher$47.8Blower
Valuation
P/E13.5lower33.6higher
P/S2.6lower4.8higher
P/B5.3higher5.1lower
Dividend yield4.00%higher1.13%lower
Profitability
Operating margin—19.5%
Balance sheet
Net assets$18.5Blower$22.4Bhigher
Total liabilities$71.5Bhigher$25.4Blower
Total debt$45.1Bhigher$15.9Blower
Cash on hand$10.2Bhigher$4Blower
Price change
Today-3.08%lower+1.53%higher
1 year+33.7%higher-13.6%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Bristol-Myers Squibb / Stryker). Who owns BMY · Who owns SYK

Further comparisons

Learn

Questions and answers

Which is bigger, Bristol-Myers Squibb or Stryker?

By market value, Bristol-Myers Squibb is the larger: $124.7B against $120.1B for Stryker. By revenue in its latest fiscal year, Bristol-Myers Squibb is the larger: $48.2B against $25.1B for Stryker.

Which has the higher P/E ratio?

Stryker: 33.6, against 13.5 for Bristol-Myers Squibb. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

Bristol-Myers Squibb: 4.00%, against 1.13% for Stryker. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Bristol-Myers Squibb: $45.1B, against $15.9B for Stryker. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Bristol-Myers Squibb and Stryker?

In their latest 13F filings, Primecap team, Jeremy Grantham (co-founder) and Mairs & Power team hold both.

Cite this page

Funkfolio, “Bristol-Myers Squibb vs Stryker”, data as of 17 November 2026. https://funkfolio.com/compare/bmy-vs-syk

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.